Abivax

ABVX

ATLANTA, GA – – (Globe Newswire – November 20, 2026) – – Holzer & Holzer, LLC is investigating whether Abivax S.A. (“Abivax” or the “Company”) (NASDAQ: ABVX) complied with federal securities laws. On November 18, 2026, Scorpion Capital published a report alleging, among other things, that obefazimod exhibits high lipophilicity, “violates one of the industry’s most basic screens for oral drug viability” and further alleges that the drug’s properties “resembles the signature of persistent organic pollutants (POPs) and certain agrochemicals.” On this news, the price of the Company’s stock dropped.

If you purchased Abivax stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/abivax/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share